CGRP mAb Subcutaneous denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits Quantities of Subcutaneous CGRP Monoclonal Antibodies — and Why You Can Appeal

Aetna's quantity-limit policy for subcutaneous CGRP monoclonal antibodies is calibrated to the dosing schedule in the FDA-approved prescribing label. The limit exists because these medications are typically administered on a monthly or quarterly schedule, and Aetna will only authorize the number of doses that align with that schedule over the authorization period. Denials occur when the quantity on the prescription does not match Aetna's expected dosing interval, when a supply requested spans a longer period than the authorization covers, or when a prescriber writes for a different administration schedule.

The good news is that quantity-limit appeals are among the most administratively resolvable — because the correct quantity is defined by the FDA label, not by Aetna's clinical judgment.

## Federal Appeal Framework

Quantity-limit denials are subject to ACA Section 2719 external review (for non-grandfathered plans) and ERISA Section 503 full-and-fair review (for employer-sponsored plans). You have approximately 180 days from the denial to file internally. If Aetna upholds the denial, request independent external review within approximately four months. Expedited review is available when the standard timeline would seriously threaten your health.

## Concrete Appeal Steps

1. Obtain the denial letter and identify the exact quantity Aetna approved versus the quantity requested. 2. Download the FDA-approved prescribing label for the specific CGRP agent from DailyMed and confirm the labeled dosing interval. 3. Verify that the prescription your prescriber submitted requests exactly the number of doses that correspond to the labeled interval for the authorization period. 4. If the quantities match and the denial still stands, escalate to a formal internal appeal; if there was a mismatch, have your prescriber correct the prescription and resubmit the PA.

## Documentation to Gather

• FDA prescribing label: confirming the labeled dosing interval and expected number of doses per authorization period
• Prescriber prescription and PA records: showing the quantity requested and the dosing schedule intended
• Aetna's published quantity-limit policy for this drug: obtained from Aetna's provider portal or clinical policy bulletins
• Prescriber note: confirming that the requested quantity matches the approved label and that no clinical deviation from standard dosing is intended

## Criteria-Mapping Structure

In your appeal, address the quantity issue as a factual matter: state the FDA-labeled dosing interval, the number of doses that implies over the authorization period, and the quantity requested. Present these side by side. If they match, the denial should be reversed on that basis alone. If Aetna's policy imposes a shorter authorization window, address whether that window is clinically appropriate given the chronic nature of migraine prevention and the approved treatment duration described in the label.